Article Text

PDF

Anticoagulation for Acute Ischaemic Stroke?
  1. Richard Kay
  1. Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong SAR, China. E-mail: lichikay{at}cuhk.ed.hk

    Abstract

    INTRODUCTION

    Six years ago, in December 1955, there appeared in the New England Journal of Medicine an article that revolutionized the way we think of stroke. I am referring, of course, to the NINDS paper ‘Tissue plasminogen activator for acute ischemic stroke’ (The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group 1995), which singularly made the FDA recognize rt-PA as still the only approved treatment for stroke. Trailing behind that landmark paper was our paper from Hong Kong, ‘Low-molecular-weight heparin for the treatment of acute ischemic stroke’ (Kay et al. 1995), which showed that an anticoagulant, nadroparin, if given subcutaneously within 48 h of stroke onset could also reduce death or disability. This paper temporarily raised the hope that there might be another treatment for stroke than thrombolysis within three hours. But as more anticoagulant trials were completed and published, that hope has evaporated. In this article

    Statistics from Altmetric.com

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.